Cell and Molecular
Medicine Company
ExCellThera is a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel curative therapies for patients with hematologic malignancies.

ExCellThera’s most advanced technology, ECT-001 Cell Therapy, combines a proprietary small molecule, UM171, and an optimized culture system for reengineered cell therapy to provide a safe one-time treatment to patients suffering from advanced blood cancers and other blood disorders. 

Our Total Cell Therapy concept combines ECT-001 Cell technology with modular add-on treatments to address any residual disease using immuno-therapies or small molecules that leverage surplus ECT-001 Cell expanded product.

Contact us


UM171 molecule is discovered, optimized and GMP synthesized pursuant to a molecular screening


Composition of matter patents filed worldwide


Initial Phase I/II clinical trial to treat blood cancers (results published in The Lancet Haematology in 2019)


FDA grants Orphan Drug Designation (ODD) for the prevention of Graft versus Host Disease


Four (4) new Phase I/II clinical trials launched in Canada and the United States in various indications


FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation


EMA grants Orphan Medicinal Product Designation as treatment in hematopoietic stem cell transplants.

ExCellThera has an experienced and well-balanced leadership team.
Contact us

Guy Sauvageau

M.D., Ph.D, FRCP(C)

Founder and Chief Executive and Scientific Officer

Internationally recognized stem cell biologist, co-identified UM171 and co-founded the Center for cell therapy of Montreal and the Quebec Leukemia Cell Bank.

David Millette

CA, CPA, CFA, Lawyer

Chief Operating and Financial Officer

Over 20 years of experience in business management and advisory services. Broad range of financial, legal and strategic experience across several industries, including pharmaceuticals, life sciences and healthcare.

Anne Marinier

M.D., Ph.D.

Co-Founder and Chief Technology Officer, Chemistry

Over 25 years of experience in medicinal chemistry and drug discovery including industry expertise, co-identified UM171. Previously, she was Group Leader in the Drug Discovery Research group at Bristol-Myers Squibb.

Peter Zandstra

Ph.D., FRSC(E)


Co-founded three biotech companies. His lab focuses on using computer modelling and strict microenvironment control to better understand regulatory networks that determine stem cell fate.

Pierre Caudrelier


Chief Medical Officer

Over 30 years of experience in various positions in the Pharma and Biotech sectors. He has published 21 articles and is inventor or co-inventor on 19 patents from 2 patent families.

Sven Ansorge


Director of Manufacturing

Over 10 years of experience in biopharmaceutical industry and research and development, possessing strong management and leadership skills. Bioprocessing expert with sound publication and presentation track record.

Contact us

Each year, tens of thousands of patients receive stem cell transplant for blood diseases, such as leukemia, multiple myeloma or sickle cell disease. Unfortunately, not everyone responds as hoped. ExCellThera is working towards reducing complications for these patients, such as transplant rejection, relapse or even death, which can be as high as 50 per cent.